Sai Life Sciences LimitedSAILIFECorporate

Healthcare Diagnostics & Research Latest results: Mar 2026 10 quarters of data

₹1,389.40

MCap ₹29,510 Cr · P/E 86.3

Sai Life Sciences Limited — Stock analysis & AI research Sai Life Sciences Limited — Multibagger AI analysis Sai Life Sciences Limited — Seasonality — best & worst months Sai Life Sciences Limited — Technical indicators & charts Sai Life Sciences Limited — Technical setup — score, trend, support & resistance Sai Life Sciences Limited — Live exchange announcements

📋 High ROCE Stocks 📋 High Operating Margin Stocks 📋 High Interest Coverage Stocks 📋 Low Debt Stocks 📋 Small Cap Stocks List 📈 20-Day Breakdown Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹594 Cr

Sales · Mar 2026

+4.8% YoY

₹168 Cr

Operating Profit · Mar 2026

+9.2% YoY

28.3%

OPM % · Mar 2026

+4.4% YoY

₹103 Cr

Net Profit · Mar 2026

+14.5% YoY

₹4.84

EPS · Mar 2026

+12.0% YoY

📝 Sai Life Sciences Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Sai Life Sciences Limited reported revenue of ₹594 crore for the quarter ended March 2026 (Q4 FY26), up 4.8% from ₹567 crore in the same quarter last year, and up 8.2% sequentially over the December 2025 quarter.

Net profit rose 14.5% year-on-year to ₹103 crore, from ₹90 crore. Earnings per share (EPS) came in at ₹4.84.

Operating profit stood at ₹168 crore — an operating margin (OPM) of 28.3%, compared with 27.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Sai Life Sciences Limited posted revenue of ₹2,153 crore, a growth of 30.3% over FY25, with a net profit of ₹342 crore (up 93.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,153 crore with a net profit of ₹342 crore.

Valuation snapshot

At the current price of ₹1,389.40, SAILIFE has a market capitalisation of ₹29,510 crore and a trailing P/E of about 86.3.

Within the Diagnostics & Research industry, it is the largest of the 3 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 34.50%, foreign institutional investors (FIIs) 19.91%, domestic institutional investors (DIIs) 32.32%, public shareholders 13.26% of Sai Life Sciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹29,510 Cr

Current Price ?

₹1,389.4

P/E ?

86.30above ind

Industry P/E ?

70.20

P/B ?

11.77

P/S ?

13.71

P/FCF ?

-313.94

Enterprise Value ?

₹29,733 Cr

EV/EBITDA ?

49.56

PEG ?

0.61

Earnings Yield ?

1.5%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹2,153 Cr

OPM ?

27.9%

Profit after tax (TTM) ?

₹342 Cr

EPS (TTM) ?

₹16.10

ROCE ?

19.0%

ROE ?

13.6%

ROA ?

9.5%

Growth

Sales — latest qtr ?

₹594 Cr

PAT — latest qtr ?

₹103 Cr

YoY qtr sales growth ?

4.8%

YoY qtr profit growth ?

14.5%

Sales growth (3y) ?

23%

Sales growth (5y) ?

23%

Profit growth (3y) ?

142%

Profit growth (5y) ?

40%

Financial Health

Debt ?

₹223 Cr

Debt to Equity ?

0.09

Interest Coverage ?

13.6

Current Ratio ?

N/A

Ownership

Promoter holding ?

34.50%

Change in promoter holding ?

-0.65%

Pledged percentage ?

N/A

Market

Return 3 months ?

9.2%

Return 6 months ?

43.1%

🗓️ Quarterly results (10 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	YoY %	QoQ %
Sales	373	428	264	382	440	567	483	527	549	594	+4.8%	+8.2%
Operating Profit	94	127	25	101	120	154	113	140	179	168	+9.2%	-6.1%
Other Income	11	4	8	10	9	10	10	15	0	16	+62.9%	—
Interest	22	19	20	19	23	9	11	8	8	6	-34.5%	-25.0%
Depreciation	28	28	28	33	34	34	34	36	41	41	+20.3%	+0.0%
Profit Before Tax	54	83	-15	58	72	120	78	111	130	137	+13.7%	+5.0%
Net Profit	40	62	-11	44	54	90	58	83	98	103	+14.5%	+5.5%
EPS	—	—	—	—	2.89	4.32	2.80	3.95	4.62	4.84	+12.0%	+4.8%
OPM %	25.2%	29.7%	9.5%	26.4%	27.2%	27.1%	23.4%	26.6%	32.6%	28.3%	+4.4%	-13.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹1,653 Cr	₹2,153 Cr	₹2,153 Cr	+30.3%
Operating Profit	₹400 Cr	₹600 Cr	₹600 Cr	+50.1%
OPM %	24.18%	27.87%	27.87%	+15.3%
NPM %	10.70%	15.88%	15.88%	+48.4%
Other Income	₹37 Cr	₹41 Cr	₹41 Cr	+11.0%
Depreciation	₹129 Cr	₹152 Cr	₹152 Cr	+17.7%
Interest	₹71 Cr	₹33 Cr	₹33 Cr	-53.7%
EBIT	₹270 Cr	₹448 Cr	₹448 Cr	+65.6%
PBT	₹235 Cr	₹456 Cr	₹456 Cr	+94.1%
Tax	₹48 Cr	—	—	—
Net Profit	₹177 Cr	₹342 Cr	₹342 Cr	+93.4%
EPS	₹7.21	₹16.21	₹16.21	+124.8%
Material Cost	₹276 Cr	—	—	—
Employee Cost	₹267 Cr	—	—	—
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	18	18	21	21	+0.0%
Reserves	895	993	2,147	2,487	+15.8%
Borrowings	869	868	287	223	-22.3%
Other Liabilities	349	361	682	872	+27.9%
Total Liabilities	2,131	2,240	3,137	3,603	+14.9%
Fixed Assets	923	1,074	1,378	1,705	+23.7%
CWIP	151	107	124	270	+117.7%
Investments	80	80	114	163	+43.0%
Other Assets	977	979	1,521	1,465	-3.7%
Total Assets	2,131	2,240	3,137	3,603	+14.9%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	221	251	330	495	+50.0%
Cash from Investing Activity	-111	-190	-565	-393	+30.4%
Cash from Financing Activity	-190	-85	314	-109	-134.7%
Net Cash Flow	-80	-24	80	-7	-108.7%
Free Cash Flow	156	72	-33	-94	-184.8%
CFO/OP	135%	92%	89%	89%	+0.0%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	87	67	78	63	-19.2%
Inventory Days	123	73	96	98	+2.1%
Days Payable	176	114	270	200	-25.9%
Cash Conversion Cycle	35	25	-96	-40	+58.3%
Working Capital Days	42	20	69	76	+10.1%
ROCE %	6%	11%	14%	19%	+35.7%

👥 Shareholding (latest 6 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026	% Chg
Promoters	35.15%	34.95%	34.70%	34.61%	34.53%	34.50%	-0.1%
FIIs	14.57%	22.50%	21.41%	21.17%	19.65%	19.91%	+1.3%
DIIs	21.64%	29.92%	31.41%	31.54%	32.71%	32.32%	-1.2%
Public	28.64%	12.65%	12.49%	12.69%	13.11%	13.26%	+1.1%
No. of Shareholders	1,26,380	1,19,705	1,14,820	1,17,527	1,25,096	1,43,124	+14.4%

⚖️ Peer comparison

Industry: Diagnostics & Research · 3 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SAILIFE SAI LIFE	₹1,585.00	33,664	95.7	2,181	343	29.0%	15.7%	29.4%	105.3%	3.8%	18.2%
2	LALPATHLAB Dr. Lal	₹1,897.00	31,676	58.5	2,892	546	29.0%	18.9%	12.3%	3.4%	19.1%	27.2%
3	SYNGENE Syngene International	₹383.10	15,420	69.8	3,600	221	22.3%	6.1%	2.6%	-36.2%	-15.8%	-110.4%

❓ Frequently asked questions

What was Sai Life Sciences Limited's revenue in Q4 FY26?

What was Sai Life Sciences Limited's net profit in Q4 FY26?